Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms

References

• Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497–515. doi: 10.1016/j.ecl.2015.05.001
   PubMed Web of Science ®Google Scholar
• Williams RE, Levine KB, Kalilani L, et al. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas. 2009;62(2):153–159. doi: 10.1016/j.maturitas.2008.12.006
   PubMed Web of Science ®Google Scholar
• Joffe H, Massler A, Sharkey KM. Evaluation and management of sleep disturbance during the menopause transition. Semin Reprod Med. 2010;28(5):404–421. doi: 10.1055/s-0030-1262900
   PubMed Web of Science ®Google Scholar
• Whiteley J, Wagner JS, Bushmakin A, et al. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013;20(5):518–524. doi: 10.1097/GME.0b013e31827d38a5
   PubMed Web of Science ®Google Scholar
• Williams RE, Kalilani L, DiBenedetti DB, et al. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007;58(4):348–358. doi: 10.1016/j.maturitas.2007.09.006
   PubMed Web of Science ®Google Scholar
• Bansal R, Aggarwal N. Menopausal hot flashes: a concise review. J Midlife Health. 2019;10(1):6–13. doi: 10.4103/jmh.JMH_7_19
   PubMedGoogle Scholar
• Col NF, Guthrie JR, Politi M, et al. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009;16(3):453–457. doi: 10.1097/gme.0b013e31818d414e
   PubMed Web of Science ®Google Scholar
• Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539. doi: 10.1001/jamainternmed.2014.8063
   PubMed Web of Science ®Google Scholar
• Joffe H, Crawford S, Economou N, et al. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep. Sleep. 2013;36(12):1977–1985. doi: 10.5665/sleep.3244
   PubMed Web of Science ®Google Scholar
• Woods NF, Hohensee C, Carpenter JS, et al. Symptom clusters among MsFLASH clinical trial participants. Menopause. 2016;23(2):158–165. doi: 10.1097/GME.0000000000000516
   PubMed Web of Science ®Google Scholar
• Kravitz HM, Zhao X, Bromberger JT, et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep. 2008;31(7):979–990.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Solomon CG. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446–455. doi: 10.1056/NEJMcp1714787
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168. doi: 10.1016/S0140-6736(19)31709-X
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1(1): CD004143. doi: 10.1002/14651858.CD004143.pub5
   PubMedGoogle Scholar
• Kim JE, Chang JH, Jeong MJ, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Sci Rep. 2020;10(1):20631. doi: 10.1038/s41598-020-77534-9
   PubMed Web of Science ®Google Scholar
• Nappi RE, Siddiqui E, Todorova L, et al. Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: a European cross-sectional survey. Maturitas. 2023;167:66–74. doi: 10.1016/j.maturitas.2022.09.006
   PubMed Web of Science ®Google Scholar
• Stute P, Cano A, Thurston RC, et al. Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States. Maturitas. 2022;164:38–45. doi: 10.1016/j.maturitas.2022.06.008
   PubMed Web of Science ®Google Scholar
• Trower M, Anderson RA, Ballantyne E, et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020;27(5):498–505. doi: 10.1097/GME.0000000000001500
   PubMed Web of Science ®Google Scholar
• Skorupskaite K, George JT, Veldhuis JD, et al. Neurokinin B receptor antagonism decreases LH secretion and sensation of hot flushes in postmenopausal women. BJOG. 2016;132:79. doi: 10.1111/1471-0528.14097
   Google Scholar
• Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flashes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809–1820. doi: 10.1016/S0140-6736(17)30823-1.
   PubMed Web of Science ®Google Scholar
• Skorupskaite K, George JT, Veldhuis JD, et al. Neurokinin 3 receptor antagonism reveals roles for neurokinin B in the regulation of gonadotropin secretion and hot flashes in postmenopausal women. Neuroendocrinolgy. 2018;106(2):148–157. doi: 10.1159/000473893
   PubMed Web of Science ®Google Scholar
• Freedman RR. Physiology of hot flashes. Am J Hum Biol. 2001;13(4):453–464. doi: 10.1002/ajhb.1077
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Hunter MS, Maki PM, et al. The menopausal hot flush: a review. Climacteric. 2017;20(4):296–305. doi: 10.1080/13697137.2017.1306507
   PubMed Web of Science ®Google Scholar
• Boulant JA. Role of the preoptic-anterior hypothalamus in thermoregulation and fever. Clinical Infectious Diseases. 2000;31(Suppl 5):S157–S161. doi: 10.1086/317521
   PubMed Web of Science ®Google Scholar
• Nakamura K, Morrison SF. A thermosensory pathway mediating heat-defense responses. Proc Natl Acad Sci, USA. 2010;107(19):8848–8853. doi: 10.1073/pnas.0913358107
   PubMed Web of Science ®Google Scholar
• Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile luteinizing hormone secreation. Science. 1979;205(4408):823–825. doi: 10.1126/science.462193
   PubMed Web of Science ®Google Scholar
• Tataryn IV, Meldrum DR, Lu KH, et al. LH, FSH and skin temperature during the menopausal hot flash. J Clin Endocrinol Metab. 1979;49(1):152–154. doi: 10.1210/jcem-49-1-152
   PubMed Web of Science ®Google Scholar
• Prague JK, Voliotis M, Clarke S, et al. Determining the relationship between hot flushes and LH pulses in menopausal women using mathematical modeling. J Clin Endocrinol Metab. 2019;104(9):3628–3636. doi: 10.1210/jc.2018-02797
   PubMed Web of Science ®Google Scholar
• Severini C, Lmprota G, Falconieri-Erspamer G, et al. The tachykinin peptide family. Pharmacol Rev. 2002;54(2):285–322. doi: 10.1124/pr.54.2.285
   PubMed Web of Science ®Google Scholar
• Oakley AE, Clifton DK, Steiner RA. Kisspeptin signaling in the brain. Endocr Rev. 2009;30(6):713–743. doi: 10.1210/er.2009-0005
   PubMed Web of Science ®Google Scholar
• Skorupskaite K, Anderson RA. Hypothalamic neurokinin signaling and its application in reproductive medicine. Pharmacol Ther. 2022;230:107960. doi: 10.1016/j.pharmthera.2021.107960
   PubMed Web of Science ®Google Scholar
• Alcin E, Sahu A, Ramaswamy S, et al. Ovarian regulation of kisspeptin neurones in the arcuate nucleus of the rhesus monkey (Macaca mulatta). J Neuroendocrinol. 2013;25:488–496. doi: 10.1111/jne.12025
   PubMed Web of Science ®Google Scholar
• Rance NE, Young WS. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology. 1991;128(5):2239–2247. doi: 10.1210/endo-128-5-2239
   PubMed Web of Science ®Google Scholar
• Rometo AM, Krajewski SJ, Lou Voytko M, et al. Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys. J Clin Endocrinol Metab. 2007;92(7):2744–2750. doi: 10.1210/jc.2007-0553
   PubMed Web of Science ®Google Scholar
• Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211–227. doi: 10.1016/j.yfrne.2013.07.003
   PubMed Web of Science ®Google Scholar
• Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep. 2015;5(1):8466. doi: 10.1038/srep08466
   PubMedGoogle Scholar
• De Muckadell Ob S, Aggestrup S, Stentoft P. Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man. Scand J Gastroenterol. 1986;21(4):498–502. doi: 10.3109/00365528609015169
   PubMed Web of Science ®Google Scholar
• Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809–1820. doi: 10.1016/S0140-6736(17)30823-1
   PubMed Web of Science ®Google Scholar
• Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a Neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104(12):5893–5905. doi: 10.1210/jc.2019-00677
   PubMed Web of Science ®Google Scholar
• Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27(4):382–392. doi: 10.1097/GME.0000000000001510
   PubMed Web of Science ®Google Scholar
• Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–1102. doi: 10.1016/S0140-6736(23)00085-5
   PubMed Web of Science ®Google Scholar
• Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023;108(8):1981–1997. doi: 10.1210/clinem/dgad058
   PubMed Web of Science ®Google Scholar
• Sassarini J, Anderson RA. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms. Expert Opin Investig Drugs. 2024;33(1):19–26. doi: 10.1080/13543784.2024.2305122
   PubMed Web of Science ®Google Scholar
• Ratti E, Bettica P, Alexander R, et al. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol. 2013;27(5):424–434. doi: 10.1177/0269881113480990
   PubMed Web of Science ®Google Scholar
• Ratti E, Carpenter DJ, Zamuner S, et al. Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia. Sleep. 2013;36(12):1823–1830. doi: 10.5665/sleep.3208
   PubMed Web of Science ®Google Scholar
• Ridler K, Gunn RN, Searle GE, et al. Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET. J Psychopharmacol. 2014;28(3):244–253. doi: 10.1177/0269881113517953
   PubMed Web of Science ®Google Scholar
• Te Beek ET, Hay JL, Bullman JN, et al. Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers. Brit J Clinical Pharma. 2013;75(5):1328–1339. doi: 10.1111/bcp.12004
   PubMed Web of Science ®Google Scholar
• Pawsey S, Mills EG, Ballantyne E, et al. Elinzanetant (NT-814), a neurokinin 1,3 receptor antagonist, reduces estradiol and progesterone in healthy women. J Clin Endocrinol Metab. 2021;106(8):e3221–e3234. doi: 10.1210/clinem/dgab108.
   PubMed Web of Science ®Google Scholar
• Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239–246. doi: 10.1097/GME.0000000000002138
   PubMed Web of Science ®Google Scholar
• FDA approves novel drug to treat moderate to severe hot flashes caused by menopause [internet]. silver spring. (MD (USA)): Food and Drug Administration; [updated 2023 May 12 [cited 2023 May 12]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause#:~:text=The%20prescribing%20information%20for%20Veozah%20includes%20a%20warning,the%20first%20nine%20months%20of%20using%20the%20medication
   Google Scholar
• Rahman UA, Kashif TB, Usman M, et al. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(50):e36592. doi: 10.1097/MD.0000000000036592
   PubMed Web of Science ®Google Scholar
• Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant [Internet]. Leverkusen (Germany): Bayer Global; [Updated 2023 Mar 19 [cited 2023 Mar 19]. Available from: https://www.bayer.com/media/en-us/positive-topline-results-from-phase-iii-long-term-study-oasis-3-support-submissions-for-marketing-authorization-for-bayers-elinzanetant
   Google Scholar